Department of Cardiology, Kanazawa Medical University, Japan.
Department of Nephrology, Kanazawa Medical University Himi Municipal Hospital, Japan.
Intern Med. 2023 Jun 15;62(12):1807-1811. doi: 10.2169/internalmedicine.9745-22. Epub 2022 Oct 19.
We herein report a patient with primary effusion lymphoma-like adult T-cell leukemia/lymphoma (PEL-like ATL) that developed during hemodialysis. A 77-year-old man developed a fever and ascites. Elevated levels of lactate dehydrogenase (LDH), calcium and soluble interleukin-2 receptor (sIL-2R) along with antibodies to human T-cell leukemia virus type 1 (HTLV-1) were seen in his blood. Lymphoma cells in ascites were positive for HTLV-1 proviral DNA, but there were no neoplastic cells in peripheral blood or bone marrow and no lymphadenopathy. He was therefore diagnosed with PEL-like ATL, acute-type. After administration of brentuximab vedotin, his serum LDH, sIL-2R and atypical cells in ascites cytology decreased. The development of novel effective molecular-targeted therapies is warranted.
我们在此报告一例在血液透析过程中发生的原发性渗出性淋巴瘤样成人 T 细胞白血病/淋巴瘤(PEL 样 ATL)患者。一名 77 岁男性出现发热和腹水。其血液中乳酸脱氢酶(LDH)、钙和可溶性白细胞介素-2 受体(sIL-2R)水平升高,同时存在抗人 T 细胞白血病病毒 1 型(HTLV-1)抗体。腹水中的淋巴瘤细胞呈 HTLV-1 前病毒 DNA 阳性,但外周血或骨髓中无肿瘤细胞,也无淋巴结肿大。因此,他被诊断为 PEL 样 ATL,急性型。接受 Brentuximab vedotin 治疗后,其血清 LDH、sIL-2R 和腹水细胞学中的异型细胞减少。需要开发新型有效的分子靶向治疗方法。